As per the research report, the size of the Asia-Pacific Transfection Reagents and Equipment market size is valued at USD 223.22 million in 2020. It is expected to grow at a CAGR of 8% to reach USD 327.98 million by 2025 during the forecast period 2020-2025. It captures a market share of 27%.
The process involving the injection of genetic material, such as DNA and RNA, into the mammal’s cells is called transfection. Transfection reagents are the compounds which contain the genetic material while the equipment is used as a delivery system.
Various technological advancements that have happened in the transfection reagents and equipment market in the past have to a certain level addressed the needs and wants of researchers and biotechnology & biopharmaceutical companies. Transfection instruments that have higher efficiency are also the result of these advancements. Further, efficient quantitative and qualitative transfection in a plethora of cells, including the hard-to-transfect cells is also the result of technological advancements.
The rise in demand for synthetic genes and an increasing number of cases of cancer are primarily driving the growth of this market. Further, technological advancements in transfections, alliances worldwide betwixt the pioneering research institutes to trigger drug discovery, augmented research and development spending along with research activities by pharmaceutical and biotechnology companies are secondary factors contributing towards the same end.
Selective effectiveness of transfection reagents is the key factor likely to hamper the growth of this market. In addition, homebrew reagents by researchers conjoined with hefty costs of transfection reagents are secondary factors contributing towards the same end.
This research report segmented and sub-segmented into the following categories:
In 2016, the academic & research institutes category is likely to command the largest market share. Although, the pharmaceutical & biotechnologies category is estimated to grow at the highest CAGR during the aforementioned forecast period.
It has the highest CAGR. It captures a similar market share as compared to Europe.
The Top companies leading in the APAC Transfection Reagents and Equipment Market profiled in the report are Thermo Fisher Scientific Inc. (U.S.), Promega Corporation (U.S.), Hoffmann-La Roche Ltd. (Switzerland), and QIAGEN N.V. (Netherlands). These companies hold a leading position in the transfection reagent and equipment market because of their well-established presence in the fields of genomics, spanning fifty countries, heavy R&D investments, and strong sales as well as distribution force. Other players in the market include Polyplus-transfection SA (France), Bio-Rad Laboratories (U.S.), Lonza Group (Switzerland), Sigma-Aldrich Corporation (U.S.), Mirus Bio LLC (U.S.), and MaxCyte Inc. (U.S.).
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Reagents
5.1.2 Instruments
5.1.3 Y-o-Y Growth Analysis, By Product
5.1.4 Market Attractiveness Analysis, By Product
5.1.5 Market Share Analysis, By Product
5.2 Method
5.2.1 Biochemical
5.2.2 Calcium Phosphate
5.2.2.1 Lipofection
5.2.2.1.1 Advantages
5.2.2.1.2 Disadvantages
5.2.2.2 Calcium Phosphate
5.2.2.2.1 Advantages
5.2.2.2.2 Disadvantages
5.2.2.3 DEAE-dextran
5.2.2.3.1 Advantages
5.2.2.3.2 Disadvantages
5.2.2.4 Dendrimers
5.2.2.4.1 Advantages
5.2.2.5.1 Disadvantages
5.2.3 Physical
5.2.3.1 Electroporation
5.2.3.1.1 Advantages
5.2.3.1.2 Disadvantages
5.2.3.2 Nucleofection
5.2.3.2.1 Advantages
5.2.3.2.2 Disadvantages
5.2.3.3.Others
5.2.3.3.1 Sonoporation
5.2.3.3.2 Genegun
5.2.3.3.3 Magnetofection
5.2.3.3.4 Optoinjection
5.2.4 Viral
5.2.4.1 Adenoviruses
5.2.4.2 Retroviruses
5.2.4.3 Adenoassociated Viruses (AAV)
5.2.5 Y-o-Y Growth Analysis, By Method
5.2.6 Market Attractiveness Analysis, By Method
5.2.7 Market Share Analysis, By Method
5.3 Application
5.3.1 Biomedical Research
5.3.1.1 Gene Expression Studies
5.3.1.2 Cancer Research
5.3.1.3 Transgenic Model
5.3.2 Protein Production
5.3.3 Therapeutic Delivery
5.3.4 Y-o-Y Growth Analysis, By Application
5.3.5 Market Attractiveness Analysis, By Application
5.3.6 Market Share Analysis, By Application
5.4 End User
5.4.1 Academic & Research Institutes
5.4.2 Pharmaceutical & Biotechnology Companies
5.4.3 Y-o-Y Growth Analysis, By End User
5.4.4 Market Attractiveness Analysis, By End User
5.4.5 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Method
6.1.3.4 By Application
6.1.3.5 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Method
6.1.4.4 By Application
6.1.4.5 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Method
6.1.5.4 By Application
6.1.5.5 By End User
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Thermo Fisher Scientific Inc. (U.S.)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Promega Corporation (U.S.)
8.3 Hoffmann-La Roche Ltd. (Switzerland)
8.4 QIAGEN N.V. (Netherlands)
8.5 Polyplus-transfection SA (France)
8.6 Bio-Rad Laboratories (U.S.)
8.7 Lonza Group (Switzerland)
8.8 Sigma-Aldrich Corporation (U.S.)
8.9 Mirus Bio LLC (U.S.)
8.10 MaxCyte Inc. (U.S.)
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
